Header Forschung

Institute of Diagnostic and Interventional Neuroradiology

The Institute of Diagnostic and Interventional Neuroradiology is one of the largest neuroradiological departments in Germany. It covers the whole spectrum of neuroradiological diagnostics and endovascular interventions. 

We closely cooperate with the departments of neurosurgery, neurology, neuropaediatrics, orthopaedics and nuclear medicine as well as with the department of radiotherapy, the OncoRay and the Helmholtz Zentrum Dresden Rossendorf. The institute is strongly involved in the oncological infrastructure of the UKD in particular in UCC and the certified Center for Neurooncology.

The facility provides the most advanced imaging technics including ASL, quantitative MRI and MR spectroscopy. It has access to three multislice and one dual-source-CT scanners, three 3T MRI scanners, one 1.5T-MRI scanner, and a PET-MRI. 

Our main fields of research include neurooncologic imaging with special focus on low-grade astrocytoma and secondary glioblastoma, including 2-hydroxyglutarat-MR-spectroscopy. Besides neurooncologic issues, our research focuses on MRI biomarkers of small vessel diseases and neurodegenerative diseases, advanced white matter imaging techniques including myelin-sensitive methods and on imaging and interventional therapy of acute ischemic stroke. 


The figure shows the process of creating quantitative MRI maps. Quantitative T1- and T2-maps are used for a more detailed tissue characterization in patients with glioma. @ courtesy of Felix Raschke


Examples of contrast enhanced T1 MR images of primary Glioblastomas showing ring enhancement, necrosis and surface (subpial) growth (top row). Examples of secondary Glioblastoma with mutation of IDH (bottom row). FLAIR and T2 show a large tumor in frontal localization, bihemispheric involvement and intratumoral cysts. Contrast enhanced T1 images depict a moderate enhancement and satellite lesions. @courtesy of Kay Engellandt

Osmotherapy for malignant cerebral edema in a phase 2 prospective, double blind, randomized,
placebo-controlled study of IV glibenclamide.
Hinson, H.E. • Sun, E. • Molyneaux, B.J. • Von Kummer, R.* • Demchuk, A. • Romero, J. • Taylor Kimberly, W. • Sheth, K.N.
Erschienen 2020 in: J STROKE CEREBROVASC 29, Seite 104916

Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of
pseudoprogression: a multi-institutional experience.
Mohammadi, H. • Shiue, K. • Grass, G.D. • Verma, V. • Engellandt, K.* • Daubner, D.* • Schackert, G. • Gondim, M.J. • Gondim, D. • Vortmeyer, A.O. • Kamer, A.P. • Jin, W. • Robinson, T.J. • Watson, G. • Yu, H.H.M. • Lautenschlaeger, T.
Erschienen 2020 in: Neurooncol Pract 7, Seite 185 – 195

Mapping of language and motor function during awake neurosurgery with intraoperative optical
Oelschlägel, M. • Meyer, T. • Morgenstern, U. • Wahl, H.* • Gerber, J.* • Reiß, G. • Koch, E. • Steiner, G. • Kirsch, M. • Schackert, G. • Sobottka, S.B.
Erschienen 2020 in: NEUROSURG FOCUS 48, Seite E3

Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy.
Raschke, F. • Seidlitz, A. • Wesemann, T.* • Löck, S. • Jentsch, C. • Platzek, I. • Petr, J. • Van Den Hoff, J. • Kotzerke, J. • Beuthien-Baumann, B. • Baumann, M. • Linn, J.* • Krause, M. • Troost, E.G.C.
Erschienen 2020 in: RADIOTHER ONCOL 150, Seite 262 – 267

Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade
gliomas: correlation with molecular groups.
Juratli, T.A. • Tummala, S.S. • Riedl, A. • Daubner, D.* • Hennig, S. • Penson, T. • Zolal, A. • Thiede, C. • Schackert, G. • Krex, D. • Miller, J.J. • Cahill, D.P.
Erschienen 2019 in: J NEURO-ONCOL 141, Seite 327 – 335

Reduced diffusion in normal appearing white matter of glioma patients following
Raschke, F. • Wesemann, T.* • Wahl, H.* • Appold, S. • Krause, M. • Linn, J.* • Troost, E.G.C.
Erschienen 2019 in: RADIOTHER ONCOL 140, Seite 110 – 115

Impact of radiation, systemic therapy and treatment sequencing on survival of patients with
melanoma brain metastases.
Rauschenberg, R. • Bruns, J. • Brütting, J. • Daubner, D.* • Lohaus, F. • Zimmer, L. • Forschner, A. • Zips, D. • Hassel, J.C. • Berking, C. • Kaehler, K.C. • Utikal, J. • Gutzmer, R. • Terheyden, P. • Meiss, F. • Rafei-Shamsabadi, D. • Kiecker, F. • Debus, D. • Dabrowski, E. • Arnold, A. • Garzarolli, M. • Kuske, M. • Beissert, S. • Löck, S. • Linn, J.* • Troost, E.G.C. • Meier, F.
Erschienen 2019 in: EUR J CANCER 110, Seite 11 – 20